These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
252 related items for PubMed ID: 15959614
1. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, Miller PD, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD. Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614 [Abstract] [Full Text] [Related]
10. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Lee YH, Song GG. Korean J Intern Med; 2011 Sep; 26(3):340-7. PubMed ID: 22016595 [Abstract] [Full Text] [Related]
15. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S. Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148 [Abstract] [Full Text] [Related]
16. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Schimmer RC, Bauss F. Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110 [Abstract] [Full Text] [Related]
18. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Miller PD. Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811 [Abstract] [Full Text] [Related]